Voulgari Olga, Goutas Dimitrios, Pergaris Alexandros, Belogiannis Konstantinos, Thymara Eirini, Kavantzas Nikolaos, Lazaris Andreas C
First Department of Pathology, School of Medicine, The National and Kapodistrian University of Athens, "Laikon" General Hospital of Athens, 11527 Athens, Greece.
Curr Issues Mol Biol. 2023 Mar 25;45(4):2767-2780. doi: 10.3390/cimb45040181.
: The aim of our study was to observe the associations between the ETS-related gene ( and the phosphatase and tensin homolog gene () immunoexpression in prostate cancer and related lesions and highlight the clinical significance of these findings. : We evaluated the immunohistochemical expression of and in a series of 151 invasive prostate adenocarcinomas, including low-grade (Gleason grade pattern 3) and high-grade (Gleason grade patterns 4, 5) morphological patterns which corresponded to 45.5% and 54.4% of the cases, respectively. Additionally, we evaluated the immunoexpression of the two markers both in foci of high-grade prostatic intraepithelial neoplasia (HGPIN), as a precursor lesion of cancer, and in foci of intraductal carcinoma of the prostate (IDCP). Finally, to ensure the malignant nature of the prostate glands examined, we employed p63 and alpha-methylacyl-CoA racemase ( expression. : We found that loss was observed in 50.7%, and positivity was detected in 41.8% of our cancerous samples. In HGPIN, loss appeared to be linked with a high-grade adjacent invasive carcinoma component which also displayed loss. As far as IDCP is concerned, immunonegativity was correlated with adjacent high-grade invasive cancer, which was also immunonegative. : Our findings suggest that the clonal expansion of invasive cancer appears to be associated with distinct immunophenotypic cellular alterations of both early and late cancer-related histological lesions. Patients with loss in HGPIN in prostate biopsies should be closely monitored due to the increased likelihood of having an associated invasive high-grade carcinoma that may have not been sampled. Given the clinical significance that derives from expression in HGPIN lesions, we suggest the routine use of immunohistochemistry in prostate cancer biopsies in which HGPIN is the only finding.
我们研究的目的是观察前列腺癌及相关病变中ETS相关基因（）和磷酸酶及张力蛋白同源基因（）的免疫表达之间的关联，并强调这些发现的临床意义。我们评估了151例浸润性前列腺腺癌中 和 的免疫组化表达，这些腺癌包括低级别（Gleason分级模式3）和高级别（Gleason分级模式4、5）形态学模式，分别占病例的45.5%和54.4%。此外，我们评估了这两种标志物在高级别前列腺上皮内瘤变（HGPIN）病灶（作为癌症的前驱病变）和前列腺导管内癌（IDCP）病灶中的免疫表达。最后，为确保所检查前列腺腺体的恶性性质，我们采用了p63和α-甲基酰基辅酶A消旋酶（）表达。我们发现，在50.7%的癌样本中观察到 缺失，在41.8%的癌样本中检测到 阳性。在HGPIN中， 缺失似乎与相邻的高级别浸润性癌成分有关，该成分也显示 缺失。就IDCP而言， 免疫阴性与相邻的高级别浸润性癌相关，该癌也为 免疫阴性。我们的研究结果表明，浸润性癌的克隆性扩增似乎与癌症相关的早期和晚期组织学病变的不同免疫表型细胞改变有关。由于前列腺活检中HGPIN出现 缺失的患者伴有未被采样的相关高级别浸润性癌的可能性增加，因此应密切监测。鉴于HGPIN病变中 表达所具有的临床意义，我们建议在仅发现HGPIN的前列腺癌活检中常规使用 免疫组化。
